$28m cashflow from investing was listed.
Disclaimer was as follows:
*** Includes the costs of operating the mine and processing facilities, and other cash costs relating to the sale of spodumene concentrate during commissioning and ramp-up of the mining operation. These costs are classified as cash flows from investing activities until such time as commercial production is declared and are capitalised against project development costs (net of the sales of spodumene concentrate (pre-production) referred to above).
Doesn't say financing costs.
Only other bulk expenditure that was listed was capex.
If you take interest costs out of that $28m figure it means they produced 30kt for around $15m. Cash costs of A$500. If they did that then they are looking quite good. I am sceptical though?
I dunno?
- Forums
- ASX - By Stock
- 1MC
- everblu capital – 29 april 2019
everblu capital – 29 april 2019, page-24
-
- There are more pages in this discussion • 103 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add 1MC (ASX) to my watchlist
(20min delay)
|
|||||
Last
3.0¢ |
Change
0.001(3.45%) |
Mkt cap ! $8.364M |
Open | High | Low | Value | Volume |
3.0¢ | 3.0¢ | 2.9¢ | $18.26K | 608.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 180223 | 3.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.1¢ | 374484 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 180223 | 0.030 |
2 | 677166 | 0.029 |
3 | 92565 | 0.028 |
1 | 61938 | 0.027 |
1 | 37074 | 0.026 |
Price($) | Vol. | No. |
---|---|---|
0.031 | 374484 | 6 |
0.032 | 92168 | 2 |
0.033 | 378549 | 3 |
0.035 | 200000 | 1 |
0.036 | 12000 | 1 |
Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
Featured News
1MC (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online